Background and Need for the Study

Approximately 25% of patients with advanced esophageal and gastric adenocarcinoma have oligometastatic disease, where cancer cells have spread to a limited number of sites. Previous studies have suggested that combining systemic therapy with local treatment, such as surgery or radiation, can improve survival in these patients. However, there has been no established medical standard for determining the optimal duration of systemic therapy. Due to the lack of randomized controlled trials, clinicians have had to rely on their own experience to make these decisions.

OMEC-5 Clinical Trial Design

To address this, the OMEC consortium, which includes over 50 specialized centers in Europe, and Amsterdam UMC have jointly designed a Phase 2 and 3 multinational clinical trial called 'OMEC-5' (NCT07000253). A total of 414 patients will be enrolled and will receive standard systemic chemotherapy combined with immune checkpoint inhibitors such as nivolumab or pembrolizumab, and HER2-targeted therapy such as trastuzumab. The trial will evaluate the optimal timing for local treatment. Patients will be randomized to either receive immediate local treatment (surgery or radiation) after 4 months of systemic therapy, or to continue systemic therapy for an additional 4 months before receiving local treatment.

Market Value and Unmet Needs

The global market for esophageal and gastric cancer treatments is currently estimated at approximately $20 billion (approximately 26 trillion Korean Won) and is rapidly expanding due to the aging population and the increasing number of new patients. In particular, the standardization of blockbuster immune checkpoint inhibitors such as Opdivo and Keytruda as first-line treatments has led to a significant increase in treatment costs. Therefore, research that optimizes the treatment sequence to reduce overtreatment is of great economic importance. This clinical trial aims to rationally shorten the duration of expensive drug administration while maximizing patient survival, which is expected to have a positive impact on reducing insurance costs and the financial burden on patients.

Clinical Significance and Future Prospects

If this study demonstrates that shortening the systemic therapy duration and providing immediate local treatment results in equivalent or superior survival rates, it is likely that global guidelines for esophageal and gastric cancer will be revised. Patients will be able to avoid the side effects and reduced quality of life associated with long-term administration of targeted and immune checkpoint inhibitors, and clinicians will have access to a clearer, data-driven standard treatment protocol. This will ultimately accelerate the realization of personalized precision medicine and serve as a catalyst for the growth of the biomarker and data analysis industries.